MedTrace Logo

Gabapentin Versus Loratadine in Uremic Pruritus

NCT05750875 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-03-16

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the efficacy of gabapentin with loratadine in reducing the severity of uremic pruritus in patients of chronic kidney disease and to compare the side effects of both drugs. The main questions it aims to answer are:

* Which drug (gabapentin versus loratadine) is more effective in reducing the severity of uremic pruritus?
* Which drug (gabapentin versus loratadine) has fewer side effects?

Participants were divided into two groups.Group A received loratadine 10mg daily and group B received gabapentin 100mg daily. Both groups were given treatment for 4 weeks.

* Participants were asked to grade the severity of pruritus on a numerical rating scale and also answer the Dermatology Life Quality Index Questionnaire (DLQI)
* Participants were also asked to report any side effects, if occurred.

Researchers compared both groups with regards to improvement in pruritus severity, DLQI score and side effects.

Conditions

  • Pruritus
  • Uremia
  • Chronic Kidney Diseases

Interventions

DRUG

Loratadine

Participants were given loratadine 10mg, oral, daily, for 4 weeks

DRUG

Gabapentin

Participants were given gabapentin 100mg, oral, daily, for 4 weeks

Sponsors & Collaborators

  • King Edward Medical University

    lead OTHER

Principal Investigators

  • Noor-Un-Nisaa Zia, MD Medicine · King Edward Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05750875 on ClinicalTrials.gov